Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system

Molecular Therapy

Volumn 12, Issue 2, 2005, Pages 307-313

  Chattopadhyay, Munmun ^a   Wolfe, Darren ^b   Mata, Marina ^a   Huang, Shaohua ^b   Glorioso, Joseph C ^b   Fink, David J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Gene therapy; Herpes simplex virus; Nerve growth factor; Neurotrophin 3; Polyneuropathy; Pyridoxine

Indexed keywords

LATENCY ASSOCIATED PEPTIDE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PROBIOTIC AGENT; PYRIDOXINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS VECTOR; HERPES SIMPLEX VIRUS VECTOR QLNT3; HERPES SIMPLEX VIRUS VECTOR SHN; HERPES SIMPLEX VIRUS VECTOR SLN; HUMAN CYTOMEGALOVIRUS; IMMEDIATE EARLY GENE; MALE; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PROMOTER REGION; RAT; SENSORY NEUROPATHY; SPINAL GANGLION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS LATENCY;

ANIMALS; ELECTROPHYSIOLOGY; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; HUMANS; MALE; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; NEUROTROPHIN 3; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; SIMPLEXVIRUS; VIRAL PROTEINS;

ANIMALIA; HUMAN HERPESVIRUS 5; SIMPLEXVIRUS;

EID: 22644431919     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.04.009     Document Type: Article

References (34)

1. N.A. DeLuca A.M. McCarthy and P.A. Schaffer Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4 J. Virol. 56 1985 558-570
2. J.C. Glorioso N.A. DeLuca and D.J. Fink Development and application of herpes simplex virus vectors for human gene therapy Annu. Rev. Microbiol. 49 1995 675-710
3. J.A. Palmer et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system J. Virol. 74 2000 5604-5618
4. J.C. Glorioso and D.J. Fink Herpes vector-mediated gene transfer in treatment of diseases of the nervous system Annu. Rev. Microbiol. 58 2004 253-271
5. M. Chattopadhyay et al. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy Brain 127 2004 929-939
6. M. Chattopadhyay et al. Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals Eur. J. Neurosci. 17 2003 732-740
7. A. Natsume et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect J. Neurotrauma. 19 2002 61-68
8. J.R. Goss W.F. Goins D. Lacomis M. Mata J.C. Glorioso and D.J. Fink Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse Diabetes 51 2002 2227-2232
9. J. Liu et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain Mol. Ther. 10 2004 57-66
10. S. Hao M. Mata W. Goins J.C. Glorioso and D.J. Fink Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect Pain 102 2003 135-142
11. J.R. Goss et al. Herpes vector-mediated expression of proenkephalin reduces pain-related behavior in a model of bone cancer pain Ann. Neurol. 52 2002 662-665
12. W.F. Goins et al. A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats J. Virol. 68 1994 2239-2252
13. V. Puskovic et al. Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo Mol. Ther. 10 2004 67-75
14. M.E. Helgren et al. Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy J. Neurosci. 17 1997 372-382
15. M. Chattopadhyay et al. In vivo gene therapy of pyridoxine-induced neuropathy by HSV-mediated gene transfer of neurotrophin-3 Ann. Neurol. 51 2002 19-27
16. S.C. Apfel J.C. Arezzo L. Lipson and J.A. Kessler Nerve growth factor prevents experimental cisplatin neuropathy Ann. Neurol. 31 1992 76-80
17. S.C. Apfel J.C. Arezzo M. Brownlee H. Federoff and J.A. Kessler Nerve growth factor administration protects against experimental diabetic sensory neuropathy Brain Res. 634 1994 7-12
18. S.C. Apfel et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial JAMA 284 2000 2215-2221
19. P.F. Pradat et al. Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy Gene Ther. 9 2002 1333-1337
20. Y. Ai et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects J. Comp. Neurol. 461 2003 250-261
21. P.F. Pradat et al. Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies Hum. Gene Ther. 12 2001 2237-2249
22. D.M. Krisky et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons Gene Ther. 5 1998 1593-1603
23. C.E. Lilley et al. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo J. Virol. 75 2001 4343-4356
24. M.C. Perez S.P. Hunt R.S. Coffin and J.A. Palmer Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo Gene Ther. 11 2004 1023-1032
25. X. Chen et al. Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture J. Virol. 74 2000 10132-10141
26. H. Berthomme J. Lokensgard L. Yang T. Margolis and L.T. Feldman Evidence for a bidirectional element located downstream from the herpes simplex virus type 1 latency-associated promoter that increases its activity during latency J. Virol. 74 2000 3613-3622
27. H. Berthomme J. Thomas P. Texier A. Epstein and L.T. Feldman Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region J. Virol. 75 2001 4386-4393
28. D.J. McGeoch A. Dolan S. Donald and F.J. Rixon Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1 J. Mol. Biol. 181 1985 1-13
29. W.F. Goins et al. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity J. Virol. 73 1999 519-532
30. J.R. Lokensgard H. Berthomme and L.T. Feldman The latency-associated promoter of herpes simplex virus type 1 requires a region downstream of the transcription start site for long-term expression during latency J. Virol. 71 1997 6714-6719
31. T. Todo et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus Mol. Ther. 2 2000 588-595
32. P. Marconi et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo Proc. Natl. Acad. Sci. USA 93 1996 11319-11320
33. D. Wolfe et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates Gene Ther. 11 2004 1675-1684
34. S. Sweitzer D. Martin and J.A. DeLeo Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain Neuroscience 103 2001 529-539